PDCD1 and neoplasm: A major challenge in CAR-T cell therapy for solid tumors is T cell exhaustion following tumor infiltration, characterized by upregulation of inhibitory receptors (e.g., PD-1, CTLA-4, LAG-3, TIM-3) and diminished proliferative capacity and antitumor activity.